BLOCADREN Drug Patent Profile

When do Blocadren patents expire, and when can generic versions of Blocadren launch?

Blocadren is a drug marketed by Merck and is included in one NDA.

The generic ingredient in BLOCADREN is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Blocadren

A generic version of BLOCADREN was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for BLOCADREN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	1
Patent Applications:	4,462
DailyMed Link:	BLOCADREN at DailyMed

Recent Clinical Trials for BLOCADREN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioHealthonomics Inc.	Phase 2
AgoneX Biopharmaceuticals, Inc.	Phase 2

See all BLOCADREN clinical trials

US Patents and Regulatory Information for BLOCADREN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for BLOCADREN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-001	Approved Prior to Jan 1, 1982	3,655,663
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-004	Approved Prior to Jan 1, 1982	3,655,663
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-002	Approved Prior to Jan 1, 1982	3,655,663

International Patents for BLOCADREN

See the table below for patents covering BLOCADREN around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	954863
Yugoslavia	32950
Sweden	389102	MELLANPRODUKT TILL ANVENDNING FOR FRAMSTELLNING AV 1,2,5-TIADIAZOLFORENINGAR MED BETA-ADRENERGISKA BLOCKERINGSEGENSKAPER SAMT FORFARANDE FOR FRAMSTELLNING AV DENNA
United Kingdom	1264558
Yugoslavia	22278
Canada	949069	THIADIAZOLE PRODUCTS AND PROCESS
Austria	294830

Supplementary Protection Certificates for BLOCADREN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306

BLOCADREN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for BLOCADREN (Timolol)

Introduction to BLOCADREN (Timolol)

BLOCADREN, also known as timolol maleate, is a non-selective beta-adrenergic receptor blocking agent used primarily to treat hypertension, myocardial infarction, and migraine headaches. Although the brand name BLOCADREN is discontinued, generic versions of timolol remain widely available and play a significant role in the pharmaceutical market.

Market Size and Growth

The global beta blockers market, which includes drugs like timolol, is experiencing steady growth. This growth is driven by the increasing prevalence of cardiovascular diseases (CVDs) and the rise in the geriatric population. According to market analysts, the global beta blockers market is projected to reach more than $14.4 billion by 2031, with a compound annual growth rate (CAGR) of 5.2% from 2023 to 2031[1].

Segmentation and Application

Beta blockers, including timolol, are predominantly used for cardiac diseases, which accounted for more than 65% of the market share in 2022. The use of beta blockers in managing hypertension, myocardial infarction, and other cardiovascular conditions is a key driver of market growth[1].

Generic Market Impact

The availability of generic versions of timolol significantly influences the market dynamics. Generic drugs are cheaper and equally effective as their brand-name counterparts, making them more accessible to a wider patient base, especially in developing countries. The faster and less expensive approval process for generic drugs allows them to be brought to market more quickly, increasing their availability and reducing healthcare costs[1].

Regional Market Performance

The Asia Pacific region is expected to see significant growth in the beta blockers market due to the increasing geriatric population and the rise in CVD cases. In North America, which accounts for the largest revenue share, the market is driven by the high prevalence of hypertension and the development of new and more effective anti-hypertensive drugs[1][3].

Competitive Landscape

The beta blockers market is fragmented, with several key players including Mylan N.V., Novartis AG, Pfizer Inc., Abbott, and Teva Pharmaceutical Industries Ltd. These companies are investing heavily in research and development to introduce new formulations with improved efficacy, safety, and tolerability. The competitive landscape is further intensified by the presence of generic manufacturers, which offer cost-effective alternatives to brand-name drugs[1].

Financial Trajectory

The financial trajectory of the beta blockers market, including generic timolol, is positive due to several factors:

• Increasing Demand: The rising incidence of CVDs and hypertension drives the demand for beta blockers.
• Cost Savings: Generic versions of timolol offer significant cost savings, making them more attractive to patients, healthcare providers, and insurance companies.
• Research and Development: Continuous investment in R&D by pharmaceutical companies to improve drug formulations and delivery systems contributes to market growth[1][3].

Distribution Channels

The distribution of beta blockers, including timolol, is primarily through hospital pharmacies and retail pharmacies. These channels are expected to continue playing a crucial role in the market, with hospital pharmacies likely to maintain a larger share due to the critical nature of the treatments involved[1].

Government and Healthcare Initiatives

Governments, healthcare providers, and insurance companies are under pressure to reduce healthcare costs. The adoption of generic medications, such as generic timolol, is encouraged through incentives like lower copays or reduced out-of-pocket costs. These initiatives further boost the market for beta blockers[1].

Key Takeaways

• The global beta blockers market, including generic timolol, is growing steadily due to the rise in CVDs and the geriatric population.
• Generic versions of timolol are cost-effective and widely adopted, contributing significantly to market growth.
• The market is fragmented with several key players investing in R&D.
• North America and the Asia Pacific region are significant markets for beta blockers.
• Distribution through hospital and retail pharmacies remains crucial.

FAQs

1. What is BLOCADREN (Timolol) used for?

BLOCADREN (Timolol) is used to treat hypertension, myocardial infarction, and migraine headaches.

2. Why is the beta blockers market growing?

The beta blockers market is growing due to the increasing prevalence of cardiovascular diseases and the rise in the geriatric population.

3. What is the impact of generic versions of timolol on the market?

Generic versions of timolol are cheaper and equally effective, making them more accessible and contributing to significant cost savings for patients and healthcare systems.

4. Which regions are expected to see significant growth in the beta blockers market?

North America and the Asia Pacific region are expected to see significant growth in the beta blockers market.

5. Who are the key players in the beta blockers market?

Key players include Mylan N.V., Novartis AG, Pfizer Inc., Abbott, and Teva Pharmaceutical Industries Ltd.

Cited Sources:

1. Transparency Market Research - Beta Blockers Market Size, Share, Growth, Industry Report - 2031
2. National Quality Forum - Cardiovascular Endorsement and Maintenance 2010: Hypertension Measures
3. Grand View Research - Anti-hypertensive Drugs Market Size & Share Report 2030
4. Federal Trade Commission - Generic Drug Industry Dynamics
5. RxList - Blocadren (Timolol): Side Effects, Uses, Dosage, Interactions